Page 34 - EFH223

El Farmacéutico Hospitales. 2022; 223: 30-34
7. Alexander BD, Winkler TP, Shi S, Dodds Ashley ES, Hickey AJ. Nebulizer delivery of micafungin aerosols. Pharmacotherapy. 2011; 31(1): 52-57 [DOI: 10.1592/phco.31.1.52].
8. Ficha técnica de voriconazol 200 mg polvo para solución
para perfusión EFG. Agencia Española del Medicamento y Productos Sanitarios (AEMPS) [consultado en abril de 2021]. Disponible en: https://cima.aemps.es/cima/dochtml/ft/80199/ FichaTecnica_80199.html
9. Mensa J, Gatell JM, García-Sánchez JE, Letang E, López-Suñé E. Guía terapéutica antimicrobiana, 28.a ed. Barcelona: Antares; 2018.
10. Tolman JA, Nelson NA, Son YJ, Bosselmann S, Wiederhold NP, Peters JI, et al. Characterization and pharmacokinetic analysis of aerosolized aqueous voriconazole solution. Eur J Pharm Biopharm. 2009; 72(1): 199-205.
11. Dupuis A, Tournier N, Le Moal G, Venisse N. Preparation and stability of voriconazole eye drop solution. Antimicrob Agents Chemother. 2009; 53(2): 798-799.
12. Kaur R, Dennison SR, Burrow AJ, Rudramurthy SM, Swami R, Gorki V, et al. Nebulised surface-active hybrid nanoparticles
of voriconazole for pulmonary Aspergillosis demonstrate clathrin-mediated cellular uptake, improved antifungal efficacy and lung retention. J Nanobiotechnology. 2021; 19(1): 19
[DOI: https://doi.org/10.1186/s12951-020-00731-1].
13. Sierra-Rodríguez T, Groover ES, Lascola KM, Mora-Pereira M,
Lee YH, Duran SH, et al. Clinical feasibility and airway deposition of nebulized voriconazole in healthy horses. J Equine Vet Sci. 2020; 94: 103246 [DOI: 10.1016/j.jevs.2020.103246]
[Epub 2020 Sep 3] [PMID: 33077094].
14. Tolman JA, Nelson NA, Bosselmann S, Peters JI, Coalson JJ, Wiederhold NP, et al. Dose tolerability of chronically inhaled voriconazole solution in rodents. Int J Pharm. 2009; 379(1): 25-31 [DOI: 10.1016/j.ijpharm.2009.06.003] [Epub 2009 Jun 11] [PMID: 19524030].
15. Tolman JA, Wiederhold NP, McConville JT, Najvar LK,
Bocanegra R, Peters JI, et al. Inhaled voriconazole for prevention of invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 2009; 53(6): 2.613-2.615 [DOI: 10.1128/AAC. 01657-08] [Epub 2009 Mar 16] [PMID: 19289523; PMCID: PMC2687213].
16. Hilberg O, Andersen CU, Henning O, Lundby T, Mortensen J, Bendstrup E. Remarkably efficient inhaled antifungal monotherapy for invasive pulmonary aspergillosis. Eur Respir J. 2012; 40(1): 271-273 [DOI: 10.1183/09031936.00163511] [PMID: 2275383].
17. Holle J, Leichsenring M, Meissner PE. Nebulized voriconazole in infections with Scedosporium apiospermum: case report and review of the literature. J Cyst Fibros. 2014; 13(4): 400-402 [DOI: 10.1016/j.jcf.2013.10.014] [Epub 2013 Nov 18. PMID: 24263169].
18. Sterling RJ. Publication decisions and their possible effects on inferences drawn from test of significance or vice versa. J Am Stat Assoc. 1959; 54: 30-34.
19. Lista NIOSH de antineoplásicos y otros fármacos tóxicos en entornos de atención médica. National Institute of Occupational Safety and Health [consultado en marzo de 2021]. Disponible en: https://www.cdc.gov/spanish/niosh/docs/2010-167_sp/ apendice.html
34
el farmacéutico hospitales n.o 223